Amyloid Cardiomyopathy Clinical Trials

6 recruiting

Amyloid Cardiomyopathy Trials at a Glance

18 actively recruiting trials for amyloid cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Dallas, Boston, and Groningen. Lead sponsors running amyloid cardiomyopathy studies include Novo Nordisk A/S, Steen Hvitfeldt Poulsen, and University of Texas Southwestern Medical Center.

Browse amyloid cardiomyopathy trials by phase

Treatments under study

About Amyloid Cardiomyopathy Clinical Trials

Looking for clinical trials for Amyloid Cardiomyopathy? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Amyloid Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Amyloid Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting

A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Pfizer1 enrolled1 locationNCT07494656
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled289 locationsNCT07207811
Recruiting
Phase 1

A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.

Transthyretin Amyloid Cardiomyopathy
Novo Nordisk A/S14 enrolled1 locationNCT07448623
Recruiting
Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company582 enrolled98 locationsNCT06563895
Recruiting

Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes

Anderson Fabry DiseaseAmyloid CardiomyopathyCardiac Magnetic Resonance Imaging+1 more
IRCCS Azienda Ospedaliero-Universitaria di Bologna250 enrolled1 locationNCT07382128
Recruiting

Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

Transthyretin (TTR) Amyloid Cardiomyopathy
University of Texas Southwestern Medical Center50 enrolled1 locationNCT07196839
Recruiting

US Benchmarking Clinical Study

Cardiac AmyloidosisHFpEF - Heart Failure With Preserved Ejection FractionHFmrEF+2 more
eMyosound SAS150 enrolled3 locationsNCT07215715
Recruiting

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Transthyretin-Related (ATTR) Familial Amyloid CardiomyopathyTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyWild-Type Transthyretin Cardiac Amyloidosis
Intellia Therapeutics72 enrolled4 locationsNCT05697861
Recruiting

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Quality of LifeTransthyretin Amyloid CardiomyopathyTransthyretin Amyloidosis+1 more
Steen Hvitfeldt Poulsen120 enrolled1 locationNCT06291805
Recruiting
Phase 1Phase 2

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

Amyloid Cardiomyopathy
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's20 enrolled1 locationNCT06634108
Recruiting

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

Amyloidosis CardiacAmyloidosis, HereditaryAmyloidosis, Familial+2 more
University of Texas Southwestern Medical Center500 enrolled3 locationsNCT05489549
Recruiting

Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)

Amyloid Cardiomyopathy
Insel Gruppe AG, University Hospital Bern300 enrolled7 locationsNCT04776824
Recruiting
Not Applicable

Exercise Training in Transthyretin Cardiac Amyloidosis

Amyloid CardiomyopathyTransthyretin Cardiac Amyloidosis
Brigham and Women's Hospital40 enrolled1 locationNCT05797857
Recruiting

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Amyloid Cardiomyopathy
Medical University of Graz189 enrolled1 locationNCT06261216
Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Myasthenia GravisAmyloidosisAlpha-Thalassemia+14 more
xCures1,000 enrolled1 locationNCT06539169
Recruiting

Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery

Transthyretin Amyloid Cardiomyopathy
Philippe Debonnaire400 enrolled1 locationNCT06101108
Recruiting
Not Applicable

Dobutamine Stress Echocardiography in LF/LG Aortic Stenosis and Wild-type Transthyretin Amyloid Cardiomyopathy

Transthyretin Amyloid CardiomyopathyAortic Stenosis
Steen Hvitfeldt Poulsen24 enrolled1 locationNCT06372301